Mitochondrial & Longevity
NAD+, NMN, and NR Research: What the Human Trials Actually Show
NAD+ is a coenzyme essential to energy metabolism that declines with age. NMN and NR are precursors the body converts into NAD+. The human-trial evidence is unusually clear on one point and unusually murky on another. Multiple controlled trials confirm that oral NMN or NR reliably raises blood NAD+ levels and is generally well tolerated (Martens et al., Nature Communications, 2018; Yoshino et al., Science, 2021). What is far less established is whether raising NAD+ produces meaningful anti-aging or healthspan benefits in humans. Raised levels are proven; downstream benefit is the open question.
- NAD+ is an energy-metabolism coenzyme that declines with age; NMN and NR are its precursors.
- Human trials confirm NMN and NR reliably raise NAD+ and are generally well tolerated.
- The leap from raised NAD+ to proven anti-aging benefit is not established in humans.
- NMN and NR are sold as research compounds or supplements depending on form and jurisdiction; regulatory status has shifted and is worth checking.
What NAD+, NMN, and NR are
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, central to converting food into usable energy and to the activity of repair enzymes. Its levels fall with age, which is the observation that launched the field. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursor molecules: the body takes them up and converts them into NAD+. So the strategy under study is simple in concept, supply a precursor and let the body rebuild its NAD+ pool.
What the trials clearly show
On the first question, the evidence is solid. Randomized human studies have demonstrated that oral NR (Martens et al., Nature Communications, 2018) and NMN (Yoshino et al., Science, 2021, and subsequent trials) raise NAD+ or its metabolites in the blood, and that both are generally well tolerated at studied doses over the studied durations. This is a real, replicated finding. The pharmacology works: you can move the NAD+ level with an oral precursor.
| Question | What the evidence says | Tier |
|---|---|---|
| Does NMN/NR raise NAD+? | Yes, replicated in human trials | Established |
| Is it generally well tolerated? | Yes, at studied doses and durations | Established (short-term) |
| Does it slow aging in humans? | Not demonstrated | Open question |
Where the evidence thins out
The second question is where honesty matters most. Raising a biomarker is not the same as improving health. Much of the exciting functional data, on lifespan, metabolism, and tissue function, comes from mouse studies. Human trials examining downstream outcomes such as insulin sensitivity and physical function have been smaller and more mixed, with some showing modest effects and others showing none. The headline claim that NAD+ precursors are proven to slow human aging runs well ahead of the data.
Where the evidence stands
This is a useful case of split tiers. That NMN and NR raise NAD+ and are generally well tolerated short-term is established in humans. That doing so produces meaningful anti-aging or healthspan benefit is not. Long-term safety and outcomes remain under investigation. Regulatory status for NMN specifically has shifted in recent years and varies, so it is worth confirming current standing. The accurate framing separates the proven pharmacology from the unproven promise.
Frequently asked questions
Do NMN and NR actually raise NAD+ in humans?
Yes. Multiple randomized human trials confirm that oral NMN or NR raises blood NAD+ or its metabolites and is generally well tolerated at studied doses.
Does raising NAD+ slow aging?
That is not established in humans. Much functional benefit comes from mouse studies; human outcome trials have been smaller and mixed. Raised levels do not automatically mean health benefit.
What is the difference between NMN and NR?
Both are NAD+ precursors. They differ by one step in the conversion pathway, and trials have studied each. Both reliably raise NAD+ in humans.
Are NMN and NR FDA approved drugs?
They are not approved drugs for anti-aging. Their regulatory status as supplements versus research compounds has shifted, especially for NMN, so current standing should be checked.
Proven pharmacology, separated from unproven promise.
The guide's NAD+ section splits what the human trials establish from what remains a mouse-level claim, with the Martens and Yoshino citations behind each point.
See the Guide
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286.
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.